Your browser version may not work well with NCBI's Web applications. More information here...
1: Crit Care. 2005;9 Suppl 5:S29-36. Epub 2005 Oct 7.
Related Articles, Links
Click here to read
Erratum in:
  • Crit Care. 2005;9(6):560.

Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.

Grounds RM, Bolan C.

Adult Intensive Care Unit, St George's Hospital, London, UK. m.grounds@blueyonder.co.uk

The hemostatic properties of recombinant activated factor VII (rFVIIa) are established in patients with inherited or acquired hemophilia with inhibitors and in patients with congenital factor VII deficiencies. Emerging clinical evidence suggests that there may be a wider role for rFVIIa in the management of hemorrhage associated with traumatic injury/accident and severe bleeding associated with critical surgery. This article considers recent data from studies in which rFVIIa was used in an attempt to control bleeding in clinical situations as diverse as coagulopathy associated with chronic liver disease, massive perioperative bleeding and bleeding during prostatectomy, organ transplantation and orthopedic surgery, uncontrollable obstetric hemorrhage, and intracerebral hemorrhage. In nontrauma settings involving acute and potentially life threatening bleeding, there may be a place for rFVIIa as adjunctive therapy in the control of hemostasis.

Publication Types:
PMID: 16221317 [PubMed - indexed for MEDLINE]